First COVID-19 patient dosed with bemcentinib

3 June 2020 | 8:53 am
BerGenBio Photo Nils Olav Mevatne
BerGenBio has announced that dosing has commenced in the Phase II clinical trial assessing bemcentinib in hospitalized COVID-19 patients. Bemcentinib was selected as the first candidate to be tested as part of the ACcelerating COVID-19 Research & Development platform (ACCORD) study, launched by the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI) on 28th […]

Cytiva associates tested for COVID-19

3 June 2020 | 8:35 am
Lotta Ljungqvist
Cytiva employees will be tested for COVID-19 infection using analysis methods developed by SciLifeLab and KTH. As well as evaluating the new method the testing will also help paint a more complete picture of the COVID-19 spread so far. Cytiva (formerly GE Healthcare Life Sciences) contributes with knowledge and resources for the development of logistics […]

Novo Nordisk leads international obesity project

3 June 2020 | 8:17 am
Novo Nordisk leads the international, public-private research consortium ‘SOPHIA’ (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), which was launched with the aim of improving risk assessment of comorbidities and treatment for people with obesity. Twenty-nine leading international partners from civil society, academia and industry have joined forces to better understand obesity and optimize […]

Novavax initiates clinical trial of COVID-19 vaccine candidate

3 June 2020 | 8:04 am
The first participants have been enrolled into a Phase 1/2 clinical trial of NVAX-CoV2373 which is being conducted at sites in Melbourne and Brisbane, Australia. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020. An investment of up to $388 million On 11 May 2020, the […]

Positive trial results from AstraZeneca

3 June 2020 | 7:48 am
Jose Baselga
The pharma company has lately announced several encouraging results from its ongoing clinical trials in lung cancer, gastric cancer, colorectal cancer and liver cancer. The Phase III ADAURA trial showed for example that treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by c. 80%. Tagrisso “The momentous […]

Oncopeptides completes Phase 3 study enrollment

3 June 2020 | 5:55 am
Jakob Lindberg
Oncopeptides has announced completion of enrollment in the phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma. The study includes 450 patients from more than 100 hospitals around the world. Results are expected to be presented later this year. About the OCEAN study OCEAN is a randomized, comparative study between melflufen and […]

Richard Hausmann resigns as President and CEO of Elekta

2 June 2020 | 7:31 pm
Richard Hausmann
Elekta has announced that Richard Hausmann, President and Chief Executive Officer, has decided to resign for personal reasons with immediate effect. “It has been a privilege to lead Elekta’s journey over the past four years, helping our customers to improve the life of millions of cancer patients around the world. I am proud to have […]

Calliditas Therapeutics launches US IPO roadshow

2 June 2020 | 11:33 am
Renee Aguiar-Lucander
Calliditas Therapeutics has launched an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States. The […]

The status of Sweden’s drug development

2 June 2020 | 11:00 am
Sara Gunnerås
SwedenBIO has released its Drug Discovery and Development Pipeline report, presenting the status of Sweden’s drug development projects in clinical and pre-clinical phases. Since the last report, 2016, the number of drug development projects has increased from 369 to 420 and at the same time, the maturity of the projects has advanced and there is […]

She is the new CFO of Bactiguard

2 June 2020 | 7:11 am
Gabriella Björknert Caracciolo
Bactiguard Holding AB (publ) has appointed Gabriella Björknert Caracciolo as new CFO and Executive Vice President. Gabriella Björknert Caracciolo is currently Head of Strategy, Development and Governance within Transaction Banking, Nordea and has been employed by the bank since 2016. Prior to that she held a number of different leading positions within Skandinaviska Enskilda Banken […]